Thromb Haemost 2003; 89(03): 590-591
DOI: 10.1055/s-0037-1613391
Letters to the Editor
Schattauer GmbH

A safety analysis of thromboprophylaxis in acute medical illness

Raza Alikhan
,
Alexander T. Cohen
Further Information

Publication History

Received 07 October 2002

Accepted after revision 03 January 2003

Publication Date:
09 December 2017 (online)

 

 
  • References

  • 1 Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA. et al Prevention of venous thromboembolism. Chest 2001; 119: 132S-S-75S
  • 2 Nicolaides AN, Breddin HK, Fareed J, Goldhaber S, Haas S, Hull R. et al Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001; 20: 1-37.
  • 3 Cohen A, Alikhan R. Prophylaxis of venous thromboembolism in medical patients. Current Opinion in Pulmonary Medicine 2001; 7: 332-7.
  • 4 Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis?. J R Soc Med 1989; 82: 203-5.
  • 5 Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C. et al A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
  • 6 Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard Delsart. et al Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14-9.
  • 7 Offord R. Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients. Pharm World Sci 2002; [In Press]
  • 8 Alikhan R. et al Use of thromboprophylaxis in nonsurgical patients: survey of a London teaching hospital. Blood 2001; 98: 1142 (abstract)
  • 9 Kleber FX, Witt C, Flosbach CW, Koppenhagen K. the PRINCE Study Group Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of Venous Thromboembolic Events in Medical Patients with Severe Cardiopulmonary Disease. Thromb Haemost 1999; 82: 1552 (abstract)
  • 10 Alikhan R, Vaughan P, Wilmott R, Osborne I, Gardner J. et al Prevention of venous thromboembolism in medical patients: a metaanalysis of the clinical trials. Br J Haematol 2002; 117 (Suppl.l) 23 (abstract 64).
  • 11 Lechler E, Schramm W, Flosbach CW. The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/ safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Haemostasis 1996; 26 (Suppl. 02) 49-56.